Neervannan Seshadri 4

What Happened
Neervannan Seshadri, Chief Operating Officer of Tarsus Pharmaceuticals, sold a total of 11,324 shares in three open-market transactions between March 17–19, 2026. The sales were: 3,125 shares at $69.42 ($216,938) on 2026-03-17; 3,610 shares at $68.71 ($248,043) on 2026-03-18; and 4,589 shares at $67.00 ($307,463) on 2026-03-19, for aggregate proceeds of approximately $772,444. These sales were reported on a Form 4 filed March 19, 2026.

Key Details

• Transaction dates & prices:
  • 2026-03-17: 3,125 shares @ $69.42 — $216,938
  • 2026-03-18: 3,610 shares @ $68.71 — $248,043
  • 2026-03-19: 4,589 shares @ $67.00 — $307,463
• Total shares sold: 11,324; total proceeds ≈ $772,444.
• Shares owned after the transactions: Not stated on this Form 4.
• Footnotes:
  • F1: The sales were "sell-to-cover" transactions to satisfy tax withholding obligations connected to the vesting/settlement of Restricted Stock Units; the sales were mandated by the issuer and not discretionary by the reporting person.
  • F2: A holding balance referenced in the filing relates to the reporting person’s daughter who shares his household; the reporting person disclaims beneficial ownership of those securities.
• Filing: Form 4 filed 2026-03-19 (covers transactions 3/17–3/19).

Context
These were sell-to-cover sales tied to RSU vesting (tax-related), which are routine and do not necessarily indicate a change in the insider’s view of the company. For retail investors, purchases can be more informative about insider sentiment; mandated tax-withholding sales are common and typically not interpreted as a discretionary bearish signal.